AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Revenio Group Oyj

Board/Management Information Mar 17, 2015

3236_iss_2015-03-17_ca1e0360-a554-4e01-ac63-f2f6d29c2f88.html

Board/Management Information

Open in Viewer

Opens in native device viewer

Disclosure 322678

Revenio Group Oyj - Changes board/management/auditors

Revenio Group Corporation: Change in Revenio's Management Team

Revenio Group Corporation Stock Exchange Release March 17, 2015 at 16:45 CHANGE IN REVENIO'S MANAGEMENT TEAM There has been a change in Revenio Group Corporation's Management Team since Revenio's Segment Director Riku Lamppu continued in his position as the CEO of Boomeranger Boats when the company was divested to International Golden Group on February 25, 2015 and at the same time his position as the Segment Director of Revenio was discontinued. Boomeranger Boats represented RIB special boat business of Revenio's Technology and Services segment that has been transferred to available-for-sale, discontinued operations. Revenio's Management Team members are CEO, chairman of the Management Team Olli- Pekka Salovaara, CEO of Icare Finland Oy Timo Hildén and Acting CFO Jasmin Kuittinen. Revenio Group Corporation Olli-Pekka Salovaara CEO Further information: President and CEO Olli-Pekka Salovaara, tel +358 40 567 5520 [email protected] www.revenio.fi Distribution: Nasdaq Helsinki Financial Supervisory Authority (FIN-FSA) Principal media www.revenio.fi The Revenio Group in brief Revenio is a Finnish health tech group whose core business lies in tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy and Oscare Medical Oy, which specialize in osteoporosis screening and assessment. In addition, Revenio has identified new growth opportunities relating to health tech in which common denominators are screening, follow-up and the global need to make cost savings in health care through preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating margin for continuing operations standing at 27,5%. The Revenio Group Corporation is listed on Nasdaq Helsinki. [HUG#1904190]

Talk to a Data Expert

Have a question? We'll get back to you promptly.